Modeling of extemporaneous oral suspensions from nystatin tablets
Abstract
In geriatrics and pediatrics, the production of extemporary liquid and solid drugs of individualized concentration from tablets is important in order to facilitate the use of medicines by patients, i.e. facilitate the dosage, method of administration, mask the unpleasant taste and smell of the medicinal substance with the help of auxiliary substances. Industrial production liquid suspensions with nystatin as an active substance for the treatment of symptoms of fungal infections and candidiasis are not registered in the Register of Medicinal Products in Lithuania. They can only be purchased for extemporal production. Therefore, it is relevant to look for ways to model modern, attractive for the patient to take a liquid drug from nystatin tablets, the need for which has remained for the treatment and improvement of candidiasis and other fungal infectious conditions. For this it is necessary to apply auxiliary substances.
Research methodology: Suspensions from nystatin tablets are produced by the method of mechanical dispersing. Suspensions are produced by the mass - volume method, applying the methodology for the production of suspensions of hydrophobic substances.
The quality of extemporal modeled drugs was evaluated after the following studies: the rate and extent of sedimentation; resuspending; organoleptic properties.
The results of the study. To stabilize extemporal medicinal suspensions with nystatin, it is recommended to use a 1% solution of hypromellose during production. When using this solution, the sedimentation of the suspension is very slow, so it is possible to accurately dose the medicinal substance. Modeled oral suspensions of extemporal production with nystatin from tablets met the applicable quality requirements, production schemes can be applied for extemporaneous production in pharmacies.
Downloads
References
2. Baldino, M. E. L., Medina-Silva, R., Sumienski, J., Figueiredo, M. A., Salum, F. G., & Cherubini, K. (2021). Nystatin effect on chlorhexidine efficacy against Streptococcus mutans as planktonic cells and mixed biofilm with Candida albicans. Clinical Oral Investigations, 1-10
3. Belayneh, A. & Tessema, Z. (2021). Review Article.A Systematic Review of the Stability of Extemporaneous Pediatric Oral Formulations. Hindawi Scientific World Journal, ID 8523091, 9.
4. Costa, R., Nascimento L. P., et al. (2020). Stability of extemporaneous sulfadiazine oral suspensions from commercially available tablets for treatment of congenital toxoplasmosis Brunna Soares. Tropical Medicine and International Health 25(3), 64–372
5. El Mershati, S., Thouvenin, A., Secretan, P. H., De Lonlay, P., Tuchmann-Durand, C., Cisternino, S., & Schlatter, J. (2021). Formulation and stability study of hydroxychloroquine sulfate oral suspensions. Pharmaceutical Development and Technology, 26(3), 328-334.
6. Gaikwad, S. S. Morales, J. O., Lande N. B., Catalán-Figueroa, J., Laddha, U. D. & Kshirsagar, S. J. (2024), Exploring paediatric oral suspension development: Challenges, requirements, and formulation advancements. International Journal of Pharmaceutics. 657(25), 124169
7. Kulshreshtha, A., K., Singh,O., N., & Michael, G. (2010). Wall Editors Pharmaceutical Suspensions. From Formulation Development to Manufacturing.
8. Neha, S. K., Sharma, V., Sharma, M., Sharma, A. K. & Madaan, V. (2022) Pharmaceutical Suspension: A Review. World Journal Of Pharmacy And Pharmaceutical Sciences 11(8), 2291-2304
9. Neves, I. & Auxtero M. D. (2021) Dosing Accuracy of Oral Extemporaneous Suspensions of Antibiotics: Measuring Procedures and Administration Devices. Pharmaceutics, 13, 528.
10. Quindós, G., Gil-Alonso, S., Marcos-Arias, C., Sevillano, E., Mateo, E., Jauregizar, N., & Eraso, E. (2019). Therapeutic tools for oral candidiasis: Current and new antifungal drugs. Medicina oral, patologia oral y cirugia bucal, 24(2), e172.
11. Rahić, O., Hadžiabdić, J., Tucak, A., Sirbubalo, M., Hindija, L., Elezović, A., & Vranić, E. (2022) A Critical Assessment of Extemporaneous Formulations for Proton Pump Inhibitors: The Importance of Proper Vehicle Selection. J Pediatr Pharmacol Ther, 27(7), 618–624
12. Rahman, S. A., Alsaedi, A. et al. (2021). Physico-Chemical and Microbiological Study for the Stability of Phenytoin Sodium Extemporaneously Compounded Suspension in Saudi Arabia Hospitals. Pharmacology & Pharmacy, 12, 1-9.
13. Saad, R., Ali, H., Ahmed, A.& El-Haj, B. (2016). Extemporaneous Furosemide Suspensions for Pediatrics Use Prepared from Commercially Available Tablets. International journal of pharmacy & pharmaceutical research
14. Sklen, Z. et al. (2013). Compounded Preparations With Nystatin For Oral And Oromucosal Administration. Acta Poloniae Pharmaceutica and Drug Research, 70(4) 759-762.
15. Vila, T., Sultan, A. S., Montelongo-Jauregui, D., & Jabra-Rizk, M. A. (2020). Oral candidiasis: a disease of opportunity. Journal of Fungi, 6(1), 15.
